Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
206 CHF | -.--% | -18.36% | -13.47% |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 32.11 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 3.91 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is not the most generous with respect to shareholders' compensation.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.47% | 66.14B | - | ||
-5.50% | 178B | C+ | ||
-5.79% | 98.95B | C | ||
-8.38% | 44.11B | B- | ||
+8.42% | 43.82B | B- | ||
+10.10% | 42.74B | B+ | ||
+10.97% | 28.92B | B | ||
+18.89% | 25.06B | A- | ||
-8.39% | 23.38B | A- | ||
-11.25% | 21.93B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BDX Stock
- 000912061 Stock
- Ratings Becton, Dickinson and Company